AZD9496

Target: This ligand targets estrogen receptor alpha (ERα/ESR1) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for estrogen receptor alpha (ERα/ESR1). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings estrogen receptor alpha (ERα/ESR1) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Based EGFR Degradation: AZD9496 can be used as a targeting ligand in PROTAC designs aimed at inducing EGFR proteolysis. By recruiting an E3 ligase to EGFR, PROTAC constructs may promote ubiquitination and lysosomal or proteasomal clearance, enabling studies of degradation-driven signaling shutdown beyond kinase inhibition.

• Resistance Mechanism Modeling: Incorporating AZD9496 into PROTAC frameworks supports mechanistic research on therapeutic resistance. Degradation of EGFR variants, including inhibitor-resistant conformations, can be compared against phosphorylation suppression to determine whether proteolysis provides broader pathway attenuation and altered downstream transcriptional responses.

• Signaling Pathway Dissection: AZD9496-based PROTACs are useful for probing causal roles of EGFR abundance in signaling networks. Time-resolved degradation experiments can quantify how loss of EGFR changes MAPK/AKT pathway dynamics, receptor trafficking, and feedback regulation, distinguishing effects of target removal from those of catalytic blockade.

• Quantitative Degradation Profiling: AZD9496 can serve as a ligand component for systematic evaluation of PROTAC efficacy and kinetics. Researchers can measure dose–response degradation curves, calculate DC50 values, and assess ternary complex dependence, providing rigorous comparisons of linker length, E3 ligase selection, and cellular context on EGFR turnover.

• Targeted Degradation in Cancer Models: AZD9496-driven PROTACs can be applied to cancer cell line studies where EGFR is a key dependency. By generating controlled degradation of EGFR, investigators can evaluate changes in proliferation, survival signaling, and compensatory receptor pathways, supporting selection of degradation-sensitive phenotypes for further PROTAC optimization.

AZD9496 is an estrogen receptor ligand containing a terminal acrylic acid handle. It can support ER-directed PROTAC construction when linker attachment preserves receptor engagement.

Structure: AZD9496 is an estrogen receptor ligand containing a tetrahydropyridoindole core, difluorophenyl acrylic acid side chain, and fluorinated alkyl substituent. The molecule includes a terminal carboxylic acid, stereochemically defined cyclic amine framework, and multiple fluorine atoms.

Reactivity: The terminal acrylic acid provides a direct vector for amide coupling to amine-terminated alkyl, PEG, piperazine, or aminoalkyl linkers, although modification may affect ER binding because the acid participates in the ligand recognition profile. For ER-directed PROTAC design, linker attachment should preserve the indole-fused core and stereochemistry. CRBN, VHL, or IAP ligands can be paired after optimizing linker length, polarity, and receptor engagement.